There was a time when a strong team, a working prototype, and a large market cleared a Series A. That time is over, and in health innovation it has been over for a while. The question investors ask has changed from can this be built to can this be sold, and they expect the answer in your numbers before they will price the round.
In practice, the bar looks like this: several million dollars in sales, credible conversion evidence, and a pipeline that survives a partner's diligence call to a buyer you did not hand-pick. Founders routinely discover this bar twelve months too late, after spending their seed round making the product better instead of making the company fundable.
Every part of the commercial proof is slower to earn in this market. Hospital sales cycles run six to twelve months. Buying committees include clinicians, IT, security, finance, and procurement, and any one of them can stall a deal. Evidence expectations mean your first customers often want a pilot before a purchase order, which adds another cycle. Meanwhile a seed-stage company is holding twelve to eighteen months of runway.
Put those numbers side by side and the conclusion is uncomfortable: a health-innovation company that starts building its commercial engine after the product is finished will usually run out of road before the proof exists.
None of this requires a big sales team. It requires a working engine: a plan, playbooks, systems, evidence, and access to buyers, run at founder speed. That is a build project with a known shape, and it is exactly the work we do.